Log in

376270 Hem Pharma, Inc. KRX · South Korea

Hem Pharma (376270) news

Hem Pharma, Inc. is a public biotech or pharmaceutical company listed on KRX under the ticker 376270, recorded under South Korea. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Hem Pharma news

We have not published a story on Hem Pharma yet. When there is news, it will appear here.

Questions about Hem Pharma

What is the ticker symbol of Hem Pharma?

Hem Pharma, Inc. trades under the ticker 376270 on KRX.

Where is Hem Pharma listed?

Hem Pharma, Inc. is listed on KRX.

Which country or territory is Hem Pharma listed under?

Our directory records Hem Pharma, Inc. under South Korea.

What does Hem Pharma do?

Our directory classifies Hem Pharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Hem Pharma?

The ISIN recorded for Hem Pharma, Inc. is KR7376270005.

Does aibio.space cover Hem Pharma?

aibio.space lists Hem Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Hem Pharma?

Companies in our directory listed in the same country and business area as Hem Pharma: CytoGen, INNOGENE Co., Helixmith Co., Onconic Therapeutics, HLB Co., Rznomics.

Investor discussion: Hem Pharma

Members talk about Hem Pharma (376270). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open KRX:376270 on TradingView.

Listing details

Hem Pharma, Inc. is a public biotech or pharmaceutical company listed on KRX under the ticker 376270, recorded under South Korea. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Hem Pharma, Inc.
Ticker
376270
Listing
KRX
Country or territory
South Korea
Business scope
Biotechnology
ISIN
KR7376270005
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.